Midatech Pharma plc (NASDAQ:MTP) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 151,400 shares, a drop of 15.7% from the March 31st total of 179,500 shares. Based on an average trading volume of 777,900 shares, the days-to-cover ratio is currently 0.2 days.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley bought a new stake in shares of Midatech Pharma in the 3rd quarter worth approximately $106,000. Virtu Financial LLC bought a new position in shares of Midatech Pharma during the fourth quarter valued at $97,000. Susquehanna International Group LLP boosted its stake in Midatech Pharma by 144.0% in the 4th quarter. Susquehanna International Group LLP now owns 84,695 shares of the company’s stock worth $159,000 after purchasing an additional 49,981 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Midatech Pharma by 18.2% during the 4th quarter. Renaissance Technologies LLC now owns 179,500 shares of the company’s stock valued at $336,000 after purchasing an additional 27,700 shares during the last quarter. Institutional investors and hedge funds own 2.27% of the company’s stock.
Shares of NASDAQ:MTP traded up $0.20 on Tuesday, hitting $2.21. The company had a trading volume of 5,834 shares, compared to its average volume of 724,227. Midatech Pharma has a 1 year low of $1.23 and a 1 year high of $7.07. The firm’s 50-day simple moving average is $2.12 and its two-hundred day simple moving average is $2.14.
About Midatech Pharma
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTD201, a long acting dose of Octreotide for the treatment of acromegaly and neuroendocrine tumors; and MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma.
Recommended Story: Current Ratio